Strategic Wealth Investment Group LLC Has $911,000 Stock Holdings in STERIS plc (NYSE:STE)

Strategic Wealth Investment Group LLC decreased its stake in shares of STERIS plc (NYSE:STE) by 5.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,432 shares of the medical equipment provider’s stock after selling 235 shares during the period. Strategic Wealth Investment Group LLC’s holdings in STERIS were worth $911,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC acquired a new position in STERIS during the 3rd quarter worth $25,000. Central Pacific Bank Trust Division acquired a new position in shares of STERIS during the third quarter valued at $28,000. Quarry LP bought a new position in STERIS in the third quarter valued at about $67,000. Asset Dedication LLC increased its position in STERIS by 54.8% in the third quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock worth $71,000 after purchasing an additional 103 shares during the period. Finally, R Squared Ltd bought a new stake in STERIS during the 4th quarter worth about $78,000. Institutional investors own 94.69% of the company’s stock.

STERIS Stock Up 0.6 %

STE stock opened at $221.66 on Friday. The company has a market cap of $21.88 billion, a price-to-earnings ratio of 50.61 and a beta of 0.84. STERIS plc has a twelve month low of $197.82 and a twelve month high of $248.24. The business has a 50 day moving average price of $211.90 and a two-hundred day moving average price of $224.77. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33.

STERIS (NYSE:STE) last released its earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.02. The business had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The firm’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the business earned $2.03 earnings per share. Analysts anticipate that STERIS plc will post 9.11 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be paid a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 annualized dividend and a yield of 1.03%. STERIS’s dividend payout ratio (DPR) is currently 52.05%.

Insider Buying and Selling

In other news, SVP Cary L. Majors sold 1,682 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.14% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a report on Friday, November 8th. Stephens restated an “overweight” rating and set a $260.00 target price on shares of STERIS in a report on Thursday, November 7th. Piper Sandler upgraded STERIS from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research report on Monday, November 18th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $262.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.